Sessions

Why So Shy? Implementing Disruptive Technologies with Confidence in Cell Therapy
Technology, Disruptive Innovation and Partnerships that are Revolutionizing How Medicines Are Made
Overcoming Scale Up Process Development Challenges for Pluripotent Stem Cell Derived Therapies
Future-Proofing Cell Therapy Production
Add It Up: 3 Things to Consider for Capacity Expansion
Unlocking the Potential of Advanced Therapies Through Collaborations

Why So Shy? Implementing Disruptive Technologies with Confidence in Cell Therapy

27 Jan 2022
08:30
Briefing Room
SPONSORED BY
Invetech

Why So Shy? Implementing Disruptive Technologies with Confidence in Cell Therapy

Introducing new technologies into a cell therapy manufacturing process presents multiple potential benefits, risks and cost. Understanding the critical decisions points that companies face as they scale their production and move towards commercialization can help manufacturers introduce disruptive technologies appropriately.

This panel will discuss:

  • Evaluation criteria for bringing in new technology
  • The factors involved in aligning platform and process development
  • Bringing disruptive technologies into the process in the context of clinical timelines
  • When is it beneficial to use something in PD before it is GMP ready?

Moderator
David Hodl, Head of Business Development, Invetech

Panellists

Matthew Li, Associate Director, Head of Cell Therapy Manufacturing Innovation, Vor Biopharma

Fabio Fachin, Head Cell Therapy Process Development, Automation and Digital Technologies, Takeda

Nicholas Ostrout, Senior Director Commercial Strategy and Implementation, Lonza

 

Speakers

David Hodl
Head of Business Development
Invetech
Matthew Li
Associate Director, Head of Cell Therapy Manufacturing Innovation
Vor Biopharma
Fabio Fachin
Head of Cell Therapy Process Development, Automation and Digital Technologies
Takeda
Nicholas Ostrout
Senior Director, Commercial Strategy and Implementation
Lonza Ltd